ArticleInternational journal of clinical and experimental pathology2020
DLEU2 participates in lymphovascular invasion and inhibits cervical cancer cell proliferation, migration, and invasion.
Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Alcohol consumption and esophageal cancer risk: unveiling DLEU2 as a key immune modulator through Mendelian randomization and transcriptomic analysis.Discover oncology · 2025Article
- Deleted in lymphocytic leukemia 2 (DLEU2): a possible biomarker that holds promise for future diagnosis and treatment of cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the roles of deleted in lymphocytic leukemia-2 (DLEU2) in the pathology of cervical cancer.
methodsDifferentially expressed long non-coding RNAs between cervical cancerous and para-cancerous tissues were examined in 26 clinical specimens by microarray analysis and quantitative real-time PCR. DLEU2 expression was correlated with clinical features in 108 patients with cervical cancer. The effects of DLEU2 on growth, proliferation, migration, and invasion were examined in cervical cancer cells.
resultsDLEU2 was correlated with lymphovascular invasion in patients with cervical cancer. DLEU2 overexpression inhibited cell proliferation, migration, and proliferation, and colony formation in cervical cancer cells.
conclusionDLEU2 is involved in the pathology of cervical cancer, and it may be a target for clinical therapy.
Indexed as
Identifiers
32922596PMC7476956W3086301316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.